Sarcoidosis-associated pulmonary hypertension : Outcome with long-term epoprostenol treatment

• Published in: Chest Vol. 130; no. 5; pp. 1481 - 1488
• Main Authors: FISHER, Kimberly A, SERLIN, David M, WILSON, Kevin C, WALTER, Robert E, BERMAN, Jeffrey S, FARBER, Harrison W
• Format: Journal Article
• Language: English
• Published: Northbrook, IL American College of Chest Physicians 01.11.2006
• Subjects: Adult; Aged; Antihypertensive Agents - adverse effects; Antihypertensive Agents - therapeutic use; Biological and medical sciences; Blood Pressure - drug effects; Blood Pressure - physiology; Cardiac catheterization; Cardiology. Vascular system; Catheters; Dose-Response Relationship, Drug; Epoprostenol - adverse effects; Epoprostenol - therapeutic use; Female; Heart; Hemodynamics; Humans; Hypertension, Pulmonary - drug therapy; Hypertension, Pulmonary - etiology; Hypertension, Pulmonary - physiopathology; Infusions, Intravenous; Intubation; Longitudinal Studies; Lung transplants; Male; Medical sciences; Middle Aged; Mortality; Patients; Pneumology; Pulmonary arteries; Pulmonary hypertension; Pulmonary hypertension. Acute cor pulmonale. Pulmonary embolism. Pulmonary vascular diseases; Retrospective Studies; Sarcoidosis; Sarcoidosis, Pulmonary - complications; Sarcoidosis, Pulmonary - physiopathology; Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis; Steroids; Treatment Outcome; Vascular Resistance - drug effects; Vascular Resistance - physiology; Veins & arteries; New York; United States > US; prostanoid therapy; Prognosis; Vasodilator agent; Prostaglandin I2; Sarcoidosis; Respiratory disease; Arachidonic acid derivatives; Cardiovascular disease; Long term; Pulmonary hypertension; Antiplatelet agent; Epoprostenol; Association; Treatment; granulomatous disease; Systemic disease; Prostanoid; Evolution; Pulmonary vascular disease; Pulmonary circulation; Prostaglandin derivatives

Pulmonary hypertension is a known complication of sarcoidosis and is associated with increased mortality. Little is known about the outcome of sarcoidosis-associated pulmonary hypertension, including response to treatment. To determine the characteristics and outcome of patients with sarcoidosis-ass...